他克莫司与吗替麦考酚酯诱导治疗活动性狼疮肾炎的10年结局:随机对照试验长期随访
该随机对照试验纳入150例活动性狼疮肾炎患者,比较他克莫司(TAC)与吗替麦考酚酯(MMF)诱导治疗后10年结局。两组完全肾脏缓解率相似(59% vs 62%,p=0.71),10年复合不良结局累积发生率均为33%(p=0.90)。首次狼疮肾炎、eGFR及6个月无应答是肾脏预后独立影响因素;18个月时uPCr>0.75和eGFR<80 mL/min best预测不良预后。
要点
- TAC诱导治疗狼疮肾炎的10年长期结局非劣于MMF。
- 18个月时uPCr≤0.75且eGFR≥80 mL/min提示10年预后良好。
- 6个月无应答与不良肾脏预后独立相关(HR 5.18)。
核心结论
- 长期数据证实他克莫司(TAC)作为狼疮肾炎诱导治疗不劣于吗替麦考酚酯(MMF)。
- 18个月时uPCr≤0.75且eGFR≥80 mL/min best预测10年良好结局,可作为诱导/巩固治疗目标。
研究设计与样本
- 随机对照试验的10年长期随访,纳入150例活动性狼疮肾炎患者(年龄35.5±12.8岁)。
- 患者接受MMF或TAC联合大剂量泼尼松龙诱导,6个月时应答者换用硫唑嘌呤(AZA)维持。
- 评估10年临床结局(肾脏复发、肾功能下降和死亡),Cox回归分析预后因素,ROC分析预测不良预后。
主要发现
- MMF组和TAC组完全肾脏缓解率相似(59% vs 62%,p=0.71)。
- 79%患者接受AZA维持治疗;随访118.2±42个月。
- 蛋白尿性肾脏复发在MMF组和TAC组分别为34%和53%,肾炎性复发分别为37%和30%(p=0.49)。
- 10年复合结局(eGFR下降≥30%、慢性肾脏病4/5期或死亡)累积发生率两组均为33%(p=0.90)。
关键数值与推荐
- ROC分析显示18个月时uPCr>0.75和eGFR<80 mL/min best预测不良肾脏预后。
- 18个月时uPCr≤0.75且eGFR≥80 mL/min best预测10年良好结局。
临床怎么用
- TAC可作为活动性狼疮肾炎的诱导治疗选择,长期结局非劣于MMF。
- 诱导治疗6个月无应答者肾脏预后较差,需加强干预。
- 18个月时uPCr≤0.75且eGFR≥80 mL/min可作为诱导/巩固治疗的目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the 10-year outcome of lupus nephritis (LN) treated with mycophenolate mofetil (MMF) or tacrolimus (TAC) induction in a randomised controlled trial. METHODS: Patients with active LN were treated with MMF or TAC combined with high-dose prednisolone. Responders were switched to azathioprine (AZA) at month 6. Clinical outcomes at 10 years (renal flares, renal function decline and mortality) were assessed. Factors affecting prognosis were studied by Cox regression. Urine protein-to-creatinine ratio (uPCr) and estimated glomerular filtration rate (eGFR) at different time points were evaluated for their prediction of a poor prognosis by receiver operating characteristic (ROC) analysis. RESULTS: 150 patients were studied (age 35.5±12.8 years). Complete renal response rate was similar between MMF (59%) and TAC-treated patients (62%; p=0.71). AZA maintenance was given to 79% patients. After 118.2±42 months, proteinuric and nephritic renal flares occurred in 34% and 37% of the MMF, and 53% and 30% of the TAC groups of patients, respectively (p=0.49). The cumulative incidence of a composite outcome of ↓eGFR ≥30%, chronic kidney disease stage 4/5 or death at 10 years was 33% in both groups (p=0.90). Factors independently associated with a poor renal prognosis were first-time LN (HR 0.12 (0.031 to 0.39); p=0.01), eGFR (HR 0.98 (0.96 to 0.99); p=0.008) and no response at month 6 (HR 5.18 (1.40 to 19.1); p=0.01). ROC analysis revealed an uPCr >0.75 and eGFR of <80 mL/min at month 18 best predicted a poor renal prognosis. CONCLUSIONS: Long-term data confirmed non-inferiority of TAC to MMF as induction therapy of LN. An uPCr≤0.75 and eGFR of ≥80 mL/min at month 18 best predicted a favourable 10-year outcome and may be suitable targets for induction/consolidation therapy. TRIAL REGISTRATION NUMBER: NCT00371319.
引用
- Mok CC, Ho LY, Ying SKY, et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis. 2020. PMID: 32448782. doi:10.1136/annrheumdis-2020-217178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。